N30 Pharma Announces FDA Approval to Initiate Phase 1 Clinical Trial for First … – PR Newswire (press release)

N30 Pharma Announces FDA Approval to Initiate Phase 1 Clinical Trial for First
PR Newswire (press release)
It is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. N6022 will initially be tested using intravenous

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *